GB201512365D0 - Novel therapy - Google Patents

Novel therapy

Info

Publication number
GB201512365D0
GB201512365D0 GBGB1512365.6A GB201512365A GB201512365D0 GB 201512365 D0 GB201512365 D0 GB 201512365D0 GB 201512365 A GB201512365 A GB 201512365A GB 201512365 D0 GB201512365 D0 GB 201512365D0
Authority
GB
United Kingdom
Prior art keywords
novel therapy
therapy
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1512365.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB1512365.6A priority Critical patent/GB201512365D0/en
Publication of GB201512365D0 publication Critical patent/GB201512365D0/en
Priority to PCT/GB2016/052119 priority patent/WO2017009644A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
GBGB1512365.6A 2015-07-15 2015-07-15 Novel therapy Ceased GB201512365D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1512365.6A GB201512365D0 (en) 2015-07-15 2015-07-15 Novel therapy
PCT/GB2016/052119 WO2017009644A1 (en) 2015-07-15 2016-07-14 Kinase inhibitors for use in the treatment of fascioscapulohumeral dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512365.6A GB201512365D0 (en) 2015-07-15 2015-07-15 Novel therapy

Publications (1)

Publication Number Publication Date
GB201512365D0 true GB201512365D0 (en) 2015-08-19

Family

ID=54013980

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1512365.6A Ceased GB201512365D0 (en) 2015-07-15 2015-07-15 Novel therapy

Country Status (2)

Country Link
GB (1) GB201512365D0 (en)
WO (1) WO2017009644A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2918588T3 (en) 2010-05-20 2017-10-31 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
EA035049B1 (en) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566310B2 (en) * 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US20150301067A1 (en) * 2012-11-05 2015-10-22 University Of Washington Through Its Center For Commercialization Methods and assays for facioscapulohumeral muscular dystrophy
CA2919952A1 (en) * 2013-03-15 2014-09-18 Dean Burkin Methods of treating muscular dystrophy
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation

Also Published As

Publication number Publication date
WO2017009644A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
PL3132034T3 (en) Therapeutic
IL257976A (en) Combination therapy
IL250387A0 (en) Combination therapy
GB201516442D0 (en) Combination therapy
GB201512365D0 (en) Novel therapy
HK1255110A1 (en) Combination therapy
GB201405033D0 (en) Combination therapy
ZA201702522B (en) Combination therapy
GB201609597D0 (en) Therapy
GB201410216D0 (en) Therapeutic
GB201519450D0 (en) Novel treatment
GB201510637D0 (en) Therapeutic
GB201505382D0 (en) Novel therapy
GB201617470D0 (en) Novel therapy
ZA201608217B (en) Combination therapy
GB201516068D0 (en) Novel therapy
GB201414542D0 (en) Novel therapy
GB201611900D0 (en) Novel therapy
GB201618477D0 (en) Therapy
GB201615923D0 (en) Macrophage-based therapy
GB201609721D0 (en) Cobination therapy
GB201609322D0 (en) Therapy
GB201609312D0 (en) Therapy
GB201518805D0 (en) Therapy
GB201603512D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)